Current Research Studies
Cancer – SC-4006: The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study
Condition or Therapy:
pediatric solid tumor, genetic testing and GAIN report
Cancer and Blood Disorders
Study Number: SC-4006
What is the goal of this study?
The goal of this study is evaluation of overall survival in pediatric patients with recurrent or refractory solid tumors who undergo successful molecular profiling to describe the overall survival of patients by treatment group (iCatM, iCatUM and UM); to identify demographic, clinical, and genomic factors associated with overall survival from the time of relapse/progression (OSr); and to store tumor material, derived cell lines/xenografts, and blood samples for general sample banking and potential future research.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are up to 30 years old, and
- Have a histologic diagnosis of solid malignancy (excluding brain tumors and lymphoma) that meets at least one of the following criteria:
- Refractory, defined as tumor progression after initiation of standard first-line therapy without having achieved a prior partial or complete remission or biopsy proven residual disease at the completion of planned standard initial front-line therapy
- Recurrent, defined as tumor progression after achieving a prior partial or complete remission
- Has newly diagnosed high-risk disease, defined as having an expected event-free survival of less than 50% at two years
- Lacks definitive diagnosis or classical genomic findings after histologic review and standard molecular testing (rare tumor group)
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
For more information, call 206-987-2106 or email the study coordinator.